|
18 Sep 2025 |
Biocon
|
Consensus Share Price Target
|
368.40 |
380.11 |
- |
3.18 |
buy
|
|
|
|
|
16 Feb 2023
|
Biocon
|
ICICI Direct
|
368.40
|
230.00
|
242.85
(51.70%)
|
Target met |
Hold
|
|
|
|
|
16 Feb 2023
|
Biocon
|
Axis Direct
|
368.40
|
260.00
|
242.85
(51.70%)
|
Target met |
Hold
|
|
|
Recommendation: We maintain HOLD on the stock
|
|
15 Feb 2023
|
Biocon
|
Motilal Oswal
|
368.40
|
250.00
|
238.10
(54.72%)
|
Target met |
Neutral
|
|
|
|
|
16 Nov 2022
|
Biocon
|
ICICI Securities Limited
|
368.40
|
362.00
|
284.40
(29.54%)
|
|
Buy
|
|
|
Biocon Limited’s (Biocon) Q2FY23 performance was ahead of our estimates led by better than expected results in the generics and research services. Generics revenue was up 17.5% YoY to Rs6.2bn while Research services delivered a robust growth of 25.9% YoY to Rs.7.7bn.
|
|
15 Nov 2022
|
Biocon
|
ICICI Direct
|
368.40
|
290.00
|
283.85
(29.79%)
|
Target met |
Hold
|
|
|
|
|
15 Nov 2022
|
Biocon
|
Axis Direct
|
368.40
|
310.00
|
283.85
(29.79%)
|
|
Hold
|
|
|
Management indicated that R&D costs will increase in the upcoming quarters which may pose threat to the current margins of the company. We, therefore, recommend a HOLD rating on the stock with a TP of Rs 310/share.
|
|
10 Aug 2022
|
Biocon
|
Geojit BNP Paribas
|
368.40
|
340.00
|
311.15
(18.40%)
|
|
Hold
|
|
|
|
|
28 Jul 2022
|
Biocon
|
ICICI Direct
|
368.40
|
320.00
|
306.75
(20.10%)
|
|
Hold
|
|
|
|
|
30 Apr 2022
|
Biocon
|
ICICI Direct
|
368.40
|
380.00
|
368.45
(-0.01%)
|
|
Hold
|
|
|
|
|
29 Apr 2022
|
Biocon
|
Axis Direct
|
368.40
|
420.00
|
368.45
(-0.01%)
|
|
Buy
|
|
|
We recommend a BUY rating on the stock with a Target Price of Rs 420.
|